Amylyx Pharmaceuticals, Inc.
AMLX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001658551
In the last 90 days, Amylyx Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 206 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $3.48M in total
- 6
- 13F holdersQ2 2026, +37 vs. previous quarter
- 206
- 13F valueReported value at the end of Q2 2026
- $2.07B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding AMLX, Q2 2026
No superinvestor reported holding AMLX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Amylyx Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 14, 2026 (view filing)4:00 PM ET | Sep 10 | 4 days | Bedrosian Camille LChief Medical Officer | SSale | −10.0K | $32.40 | −$324.9K | −3.5%278.1K after | 2 lots |
| Sep 14, 2026 (view filing)4:00 PM ET | Sep 10 | 4 days | Frates James MChief Financial Officer | SSale | −10.8K | $32.36 | −$349.8K | −4.4%233.6K after | 2 lots |
| Sep 14, 2026 (view filing)4:00 PM ET | Sep 10 | 4 days | Mazzariello GinaChief Legal Officer | SSale | −9.54K | $32.46 | −$309.5K | −4.8%190.8K after | 2 lots |
| Sep 14, 2026 (view filing)4:00 PM ET | Sep 10 | 4 days | Klee Justin B.Co-Chief Executive Officer | SSale | −30.5K | $32.18 | −$980.3K | −0.8%3.61M after | 2 lots |
| Sep 14, 2026 (view filing)4:00 PM ET | Sep 10 | 4 days | Cohen Joshua BCo-Chief Executive Officer | SSale | −30.5K | $32.19 | −$980.5K | −0.8%3.61M after | 2 lots |
| Jul 13, 2026 (view filing)4:00 PM ET | Jul 9-10 | 4 days | Mazzariello GinaChief Legal Officer | SSale | −30.0K | $17.96 | −$538.9K | −14.3%179.1K after | 2 lots10b5-1 |
| May 26, 2026 (view filing) | May 21 | 5 days | Firestone KarenDirector | PPurchase | +3.80K | $13.51 | +$51.3K | +6.0%66.9K after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Klee Justin B.Co-Chief Executive Officer | SSale | −29.3K | $14.47 | −$423.7K | −0.9%3.33M after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Cohen Joshua BCo-Chief Executive Officer | SSale | −29.3K | $14.48 | −$424.0K | −0.9%3.33M after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Bedrosian Camille LChief Medical Officer | SSale | −6.46K | $14.58 | −$94.2K | −3.7%169.3K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Amylyx Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 16,727,909 | $300.4M | 0.01% | +97,368+0.6% | Added |
| BlackRock, Inc. | 8,827,085 | $158.5M | 0.00% | −1,7510.0% | Reduced |
| Perceptive Advisors LLC | 8,334,882 | $149.7M | 2.32% | +50,000+0.6% | Added |
| TCG Crossover Management, LLC | 6,243,812 | $112.1M | 2.70% | 00.0% | Unchanged |
| Commodore Capital LP | 5,650,000 | $101.5M | 6.04% | 00.0% | Unchanged |
| Jupiter Topco LLC | 5,236,102 | $94.0M | 0.04% | +5,236,102 | New |
| Saturn V Capital Management LLC | 4,624,101 | $83.0M | 11.91% | +274,216+6.3% | Added |
| Vanguard Capital Management LLC | 4,224,224 | $75.9M | 0.00% | +82,649+2.0% | Added |
| Morgan Stanley | 3,130,808 | $56.2M | 0.00% | +955,261+43.9% | Added |
| Driehaus Capital Management LLC | 3,036,970 | $54.5M | 0.32% | +49,823+1.7% | Added |